Medically reviewed by Doru Paul, MD Key Takeaways A JAK2 mutation can make your body produce too many blood cells.  JAK2 ...

ZRSR2 mutations are linked to JAK2 V617R-driven MPNs but are insufficient alone for disease progression. CRISPR-Cas9 studies showed ZRSR2 loss causes intron retention and transcriptional changes ...

Myeloproliferative neoplasms (MPNs) represent a cluster of conditions characterized by the excessive production of blood cells within the bone marrow. Among MPN patients, abnormal quantities of red ...

While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for ...

The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive ...

The JAK2 gene mutation discovery led to JAK inhibitors, transforming myelofibrosis treatment by targeting the JAK-STAT pathway. Four FDA-approved JAK inhibitors for myelofibrosis include Jakafi, ...

A decision to rename myeloproliferative neoplasms led to a plethora of developments in a space where there was once little interest. Name recognition. The term is often associated with Fortune 500 ...